See more : Cullen Resources Limited (CUL.AX) Income Statement Analysis – Financial Results
Complete financial analysis of ORIC Pharmaceuticals, Inc. (ORIC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ORIC Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- A.P. Møller – Mærsk A/S (MAERSK-B.CO) Income Statement Analysis – Financial Results
- Rajasthan Gases Limited (RAJGASES.BO) Income Statement Analysis – Financial Results
- Tohokushinsha Film Corporation (2329.T) Income Statement Analysis – Financial Results
- Elementis plc (ELMTY) Income Statement Analysis – Financial Results
- DroneShield Limited (DRSHF) Income Statement Analysis – Financial Results
ORIC Pharmaceuticals, Inc. (ORIC)
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.03M | 966.00K | 897.00K | 970.00K | 1.00M | 900.00K | 900.00K |
| Gross Profit | -1.03M | -966.00K | -897.00K | -970.00K | -1.00M | -900.00K | -900.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 85.17M | 61.68M | 56.86M | 35.92M | 22.84M | 19.03M | 19.13M |
| General & Administrative | 25.61M | 25.09M | 22.01M | 13.42M | 5.73M | 3.35M | 3.42M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -900.00K |
| SG&A | 25.61M | 25.09M | 22.01M | 13.42M | 5.73M | 3.35M | 2.52M |
| Other Expenses | 0.00 | 5.00M | 15.00K | 177.00K | 289.00K | 233.00K | 0.00 |
| Operating Expenses | 110.78M | 86.77M | 78.87M | 49.34M | 28.57M | 22.37M | 21.64M |
| Cost & Expenses | 110.78M | 86.77M | 78.87M | 49.34M | 28.57M | 22.37M | 22.54M |
| Interest Income | 10.08M | 2.65M | 141.00K | 306.00K | 1.40M | 775.00K | 251.00K |
| Interest Expense | 0.00 | 2.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.03M | 966.00K | 897.00K | 970.00K | 1.00M | 900.00K | 900.00K |
| EBITDA | -109.75M | -91.77M | -77.97M | -74.19M | -27.54M | -20.46M | -21.13M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -110.78M | -91.77M | -78.87M | -74.19M | -28.57M | -22.37M | -22.54M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 10.08M | 2.65M | 156.00K | 483.00K | 1.69M | 1.01M | 512.00K |
| Income Before Tax | -100.70M | -89.12M | -78.72M | -73.70M | -26.88M | -21.36M | -22.03M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.36M | -1.04M | 23.57M | -1.40M | -1.01M | 0.00 |
| Net Income | -100.70M | -91.48M | -77.68M | -97.27M | -25.49M | -21.36M | -22.03M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.96 | -2.31 | -2.05 | -4.43 | -0.85 | -1.12 | -0.74 |
| EPS Diluted | -1.96 | -2.31 | -2.05 | -4.43 | -0.85 | -1.12 | -0.74 |
| Weighted Avg Shares Out | 51.45M | 39.66M | 37.95M | 21.94M | 29.90M | 19.14M | 29.90M |
| Weighted Avg Shares Out (Dil) | 51.45M | 39.66M | 37.95M | 21.94M | 29.90M | 19.14M | 29.90M |
ORIC Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
ORIC Pharmaceuticals to Host ASH Conference Call with Key Opinion Leader to Discuss Potential of ORIC-533 in Multiple Myeloma
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals to Present Update on CD73 Inhibitor Program in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting
ORIC Pharma's Shares Plunge As Initial ORIC-101 Data In Prostate Cancer Fails To Impress Investors
ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC
ORIC Pharmaceuticals Announces Multiple Data Presentations at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Global HER2 Targeting Therapies Market Trends and Forecasts, 2021-2030 - ResearchAndMarkets.com
ORIC Pharmaceuticals Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor
ORIC Pharmaceuticals Appoints Steven L. Hoerter to its Board of Directors
Source: https://incomestatements.info
Category: Stock Reports